Abstract
Ubiquitin-like with PHD and ring finger domains 1 (UHRF1), known as ICB90 or Np95, has been found to be overexpressed in numerous cancers. In this study, we evaluated the expression level of UHRF1 in ovarian cancer. UHRF1 levels in paired ovarian cancer tissues and adjacent normal tissues from 80 ovarian cancer patients were detected using relative quantitatively PCR and Western blot. Small interfering RNA (siRNA) was introduced in two human ovarian cancer cell lines (SKOV-3 and OVCAR-3) to downregulate the expression of UHRF1. The proliferation of siRNA-treated cells was examined using cell counting kit-8 (CCK-8) assay. The growth of these cells showed a remarkable decrease. Moreover, flow cytometric and Hoechst 33342 assays were used to detect the apoptosis. The diagnostic value of UHRF1 messenger RNA (mRNA) expression in ovarian cancer was estimated by receiver-operator characteristic (ROC) curve. The correlation between UHRF1 mRNA expression and clinicopathologic features of ovarian cancer patients was evaluated by χ 2 test. Our results demonstrated that both UHRF1 mRNA and protein were highly expressed in ovarian cancer tissues and significantly higher than that in adjacent normal tissues. Moreover, the inhibition of UHRF1 may lead to cells to undergo apoptosis. Thus, UHRF1 could act as a new oncogenic factor in ovarian cancer and be a potential molecular target for ovarian cancer gene therapy.
Similar content being viewed by others
References
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics [J]. CA Cancer J Clin. 2002;52(1):23–47.
Breuer EK, Murph MM. The role of proteomics in the diagnosis and treatment of women’s cancers: current trends in technology and future opportunities [J]. Int J Proteomics. 2011; pii: 373584.
Bronner C, Achour M, Arima Y, et al. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future [J]? Pharmacol Ther. 2007;115(3):419–34.
Yang GL, Zhang LH, Bo JJ, et al. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer [J]. Med Oncol. 2012;29(2):842–7.
Lallous N, Legrand P, McEwen AG, et al. The PHD finger of human UHRF1 reveals a new subgroup of unmethylated histone H3 tail readers [J]. PLoS ONE. 2011;6(11), e27599.
Chignola F, Gaetani M, Rebane A, et al. The solutionstructure of the first PHD finger of autoimmune regulator in complex with nonmodified histone H3 tail reveals the antagonistic role of H3R2 methylation [J]. Nucleic Acids Res. 2009;37(9):2951–61.
Chakravarty S, Zeng L, Zhou MM. Structure and site-specific recognition of histone H3 by the PHD finger of human autoimmune regulator [J]. Structure. 2009;17(5):670–9.
Ramon-Maiques S, Kuo AJ, Carney D, et al. The plant homeodomain finger of RAG2 recognizes histone H3 methylated at both lysine-4 and arginine-2 [J]. Proc Natl Acad Sci U S A. 2007;104(48):18993–8.
Unoki M, Kelly JD, Neal DE, et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer [J]. Br J Cancer. 2009;101(1):98–105.
Sabatino L, Fucci A, Pancione M, et al. UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigeneticsilencing and mediates colorectal cancer progression [J]. Oncogene. 2012;31(49):5061–72.
Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma [J]. Gastroenterology. 2005;129(5):1454–63.
Babbio F, Pistore C, Curti L, et al. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression [J]. Oncogene. 2012;31(46):4878–87.
Daskalos A, Oleksiewicz U, Filia A, et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer [J]. Cancer. 2011;117(5):1027–37.
Wang F, Yang YZ, Shi CZ, et al. UHRF1 promotes cell growth and metastasis through repression of p16ink4a in colorectal cancer [J]. Ann Surg Oncol. 2012;19(8):2753–62.
Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions [J]? Hum Pathol. 2005;36(10):1101–7.
Yan F, Tan XY, Geng Y, et al. Inhibition effect of siRNA-downregulated UHRF1 on breast cancer growth [J]. Cancer Biother Radiopharm. 2011;26(2):183–9.
Jenkins Y, Markovtsov V, Lang W, et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth [J]. Mol Biol Cell. 2005;16(2):5621–9.
Alhosin M, Sharif T, Mousli M, et al. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties [J]. J Exp Clin Cancer Res. 2011;30:41–50.
Greger V, Debus N, Lohmann D, et al. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma [J]. Hum Genet. 1994;94(5):491–6.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer [J]. Nat Rev Genet. 2002;3(6):415–28.
Jones PA, Baylin SB. The epigenomics of cancer [J]. Cell. 2007;128(4):683–92.
Baylin SB, Ohm JE. Epigenetic gene silencing in cancer a mechanism for early oncogenic pathway addiction [J]? Nat Rev Cancer. 2006;6(2):107–16.
Fleuriel C, Touka M, Boulay G, et al. HIC1 (hypermethylated in cancer 1) epigenetic silencing in tumours [J]. Int J Biochem Cell Biol. 2009;41(1):26–33.
Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukaemia and Burkitt’s lymphoma is associated with 5’CpG island methylation [J]. Cancer Res. 1999;59:3352–6.
Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation [J]. Blood. 1999;94(3):1113–20.
Acknowledgments
This work was financially supported by the National Natural Science Foundation of China (21475063), Jiangsu Provincial Special Program of Medical Science (BL2013036), and the Grand of Medicine Leading Talents of Jiangsu Health Department (LJ201131)
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yan, F., Wang, X., Shao, L. et al. Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth. Tumor Biol. 36, 8887–8893 (2015). https://doi.org/10.1007/s13277-015-3638-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-3638-1